David J Schlanger bought $2.2M of Progyny (PGNY)
Executed Dec 26 2024, disclosed Dec 26 2024, the same day.
Over the 21 trading sessions from the disclosed entry session (Dec 26 2024), the stock returned +63.7% (delay-adjusted); from the execution session (Dec 26 2024), +63.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
David J Schlanger (Executive Chairman) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Progyny, Inc. (PGNY). Across 1 priced purchase filing, the average 21-session return was +63.7% from execution and +63.7% from disclosure (delay-adjusted; derived). The largest single filing was $2.2M of PGNY (150,000 sh × $14.68, as filed), executed Dec 26 2024.
Healthcare · Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United Stat…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→